Retatrutide Canada: Triple-Agonist Research Peptide Guide (2026)
Share
Retatrutide Canada: Triple-Agonist Research Peptide Guide (2026)
By the ThePeptide Research Team · Verified against lot certificates RETA-0626-01 (Testides), CS-re20-0710 and CS-re30-0718 (Janoshik) · Last updated August 29, 2026
Retatrutide (development code LY-3437943) is an investigational triple-hormone-receptor agonist that activates the GIP, GLP-1, and glucagon receptors from a single lipidated peptide. Developed by Eli Lilly, it is the first triple agonist to reach Phase 3 and the current frontier of incretin-based metabolic research. This guide is a complete reference for Canadian laboratory researchers: molecular profile, mechanism, pharmacokinetics, the Phase 2 and Phase 3 TRIUMPH data, safety findings, third-party purity, current Canadian pricing, and domestic sourcing of Retatrutide 10mg, 20mg and 30mg.
Retatrutide (LY-3437943) is an investigational triple-agonist research peptide that activates the GIP, GLP-1, and glucagon receptors from one molecule. It is the first triple agonist to reach Phase 3 (the TRIUMPH program) and is studied as a reference compound in comparative incretin-receptor pharmacology. In Canada it is sold strictly as a research-use-only laboratory compound, priced at $90.00 CAD for a 10 mg vial ($9.00/mg), with 20 mg ($140.00, $7.00/mg) and 30 mg ($180.00, $6.00/mg) vials also in stock, each with a published lot certificate. It is not approved by Health Canada or the FDA.
Eli Lilly reported topline results from two more Phase 3 trials, TRIUMPH-2 (adults with type 2 diabetes) and TRIUMPH-3 (established cardiovascular disease). With TRIUMPH-1, -2 and -3 now read out, Lilly said it has "the clinical data package to support global submissions," with a U.S. regulatory filing anticipated in 2027. Retatrutide remains investigational and is not approved. See the clinical section ↓
Key takeaways
- The only triple agonist in Phase 3. Retatrutide activates GIP, GLP-1, and glucagon receptors — one more pathway than tirzepatide, two more than semaglutide.
- The triple-agonist frontier. Retatrutide adds glucagon-receptor activity to the GIP/GLP-1 pair — the pharmacology that distinguishes it from tirzepatide and semaglutide.
- Full pivotal package now reported. TRIUMPH-1 (obesity), TRIUMPH-2 (type 2 diabetes) and TRIUMPH-3 (cardiovascular disease) have all read out — global submissions expected in 2027.
- Three lots, three published certificates. 10 mg at 99.68% (lot RETA-0626-01, Testides), 20 mg at 99.643% (lot CS-re20-0710) and 30 mg at 99.751% (lot CS-re30-0718), the last two on a Janoshik blind test. See all three certificates ↓
- $90.00 CAD for 10 mg ($9.00/mg). 20 mg ($140.00 CAD, $7.00/mg) and 30 mg ($180.00 CAD, $6.00/mg — best per-mg price) are now in stock. See the price table ↓
- Research use only. Investigational; not approved by Health Canada or the FDA, not for human consumption.
- Made in Canada, shipped domestically with free, tracked Canada-wide shipping and no minimum order.
Retatrutide Quick Facts
| Compound class | Triple hormone-receptor agonist (GLP-1 / GIP / glucagon) |
|---|---|
| Development code | LY-3437943 (Eli Lilly) |
| CAS number | 2381089-83-2 |
| Peptide length | 34 amino acids, lipidated (fatty-acid modified) |
| Synthesis | Solid-phase peptide synthesis (SPPS) |
| Form | Lyophilized powder — 10 mg, 20 mg and 30 mg vials, all in stock |
| Verified purity | 10 mg: 99.68% by HPLC-UV (214 nm), lot RETA-0626-01 (Testides) · 20 mg: 99.643%, lot CS-re20-0710 (Janoshik, blind test) · 30 mg: 99.751%, lot CS-re30-0718 (Janoshik, blind test). Certificates for each ↓ |
| Storage | Lyophilized (sealed): store cool and dark; -20°C long-term. |
| Clinical status | Phase 3 (TRIUMPH program), investigational |
| Origin | Made and shipped in Canada |
| Price | $90.00 CAD for 10 mg — $9.00/mg (SKU RETA-10MG). 20 mg $140.00 CAD ($7.00/mg) and 30 mg $180.00 CAD ($6.00/mg), both in stock. Full price table ↓ |
What Is Retatrutide?
Retatrutide is a synthetic peptide engineered to act on three metabolic hormone receptors simultaneously: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon (GCGR) receptor. This "triple agonist" design distinguishes it from earlier incretin compounds that engage only one or two of those pathways — the single-target GLP-1 agonist semaglutide and the dual GIP/GLP-1 agonist tirzepatide.
In the research literature, retatrutide has been studied primarily as a candidate for obesity and related metabolic conditions. It is supplied for laboratory work as a lyophilized (freeze-dried) powder that is dissolved in a suitable solvent for in-vitro assays. Because it remains investigational and has no marketing approval from any regulator, all handling occurs within a research-use-only framework.
Molecular Profile
Retatrutide is a large, lipidated peptide of 34 amino acids, produced by solid-phase peptide synthesis and carrying a fatty-acid modification. That lipidation is functionally important: it promotes reversible binding to serum albumin, which is the structural basis for the extended circulation time discussed in the pharmacokinetics section below.
| CAS number | 2381089-83-2 |
|---|---|
| Development code | LY-3437943 |
| Class | Triple GLP-1 / GIP / glucagon receptor agonist |
| Amino-acid length | 34 residues |
| Structural feature | Fatty-acid lipidation (albumin-binding) |
| Originator | Eli Lilly and Company |
Verifying identity and purity against a Certificate of Analysis is standard practice before a lot enters any protocol. ↑ Back to top
The Triple-Agonist Mechanism: Why It's Different
The defining feature of retatrutide is that it combines three complementary signaling pathways in one molecule. Each receptor contributes a different physiological effect observed in the published research:
- GLP-1 receptor — associated with enhanced glucose-dependent insulin secretion and appetite modulation.
- GIP receptor — a second incretin pathway that acts alongside GLP-1 signaling.
- Glucagon (GCGR) receptor — the added third arm, associated with increased energy expenditure and reduced hepatic (liver) fat — the metabolic-rate pathway that tirzepatide and semaglutide do not engage.
This is precisely where retatrutide diverges from its comparators. Tirzepatide is a dual GIP/GLP-1 agonist; semaglutide is a single GLP-1 agonist. Retatrutide layers glucagon-receptor agonism on top of the GIP + GLP-1 activity, making it the first triple agonist to advance to Phase 3. Researchers hypothesize that pairing appetite-related incretin signaling with a metabolic-rate pathway is what drives the larger weight reductions reported in its trials — the mechanism explored in depth in our three-way comparison guide. ↑ Back to top
Pharmacokinetics & Half-Life
Retatrutide has an elimination half-life of approximately six days (around 144 hours) — the pharmacokinetic property behind its extended duration of action. That long half-life comes from the fatty-acid lipidation: the peptide binds reversibly to serum albumin, which slows clearance and keeps it in circulation over an extended interval.
Because clearance is slow, blood levels build gradually and reach steady state over roughly four to five weeks in pharmacokinetic studies.
For laboratory work, the practical consequence is that concentration accuracy matters when characterising the material; identity and purity should be confirmed against the Certificate of Analysis before a lot enters a protocol. ↑ Back to top
Clinical Research: Phase 2 and TRIUMPH Phase 3 Data
Two bodies of published data anchor retatrutide's scientific profile. The figures below are reported outcomes from the trials themselves — they describe the concentrations administered to trial participants under clinical supervision and are not guidance for any reader.
The Phase 2 obesity trial in the New England Journal of Medicine (Jastreboff et al., 2023) evaluated retatrutide against placebo across a range of concentrations over 48 weeks. Eli Lilly then reported topline results from Phase 3 TRIUMPH-1 in May 2026, and on July 23, 2026 added two further pivotal readouts — TRIUMPH-2 (adults with type 2 diabetes) and TRIUMPH-3 (adults with established cardiovascular disease). Full endpoints are in the primary publications and releases referenced below.
Primary documentation: the NEJM Phase 2 paper, Eli Lilly's July 23, 2026 TRIUMPH-2/-3 release, and the ClinicalTrials.gov TRIUMPH listings. ↑ Back to top
TRIUMPH-2 and TRIUMPH-3: the July 2026 readouts
TRIUMPH-2 studied 1,152 adults with type 2 diabetes and obesity or overweight across multiple concentration arms versus placebo over 80 weeks. See the primary release for the reported endpoints.
TRIUMPH-3 studied 1,949 adults with severe obesity (BMI ≥35) and established cardiovascular disease over 80 weeks — the first retatrutide readout in a higher-risk cardiovascular population. See the primary release for the reported endpoints.
Cardiovascular findings (TRIUMPH-3): what the data did and did not show
TRIUMPH-3 was the first retatrutide trial to look at major adverse cardiovascular events (MACE) as a pre-specified analysis. The result was neutral rather than clearly protective: there were 44 MACE in the pooled retatrutide arms versus 52 on placebo, and the five-component MACE-5 hazard ratio was 0.82 (95% CI 0.55–1.22) — a confidence interval that crosses 1.0, meaning the difference did not reach statistical significance. Lilly noted that cardiovascular events "occurred less frequently than anticipated in both retatrutide and placebo arms," which limits what an 80-week trial of this size can detect.
TRIUMPH-3 also reported changes in cardiovascular risk factors such as triglycerides, non-HDL cholesterol, and high-sensitivity C-reactive protein; the trial was not powered or long enough to demonstrate a reduction in cardiovascular events, which is the remit of the much larger, longer TRIUMPH-Outcomes study. All figures describe outcomes in the published clinical trial population and are reported here for scientific reference only. ↑ Back to top
The TRIUMPH Phase 3 program
TRIUMPH-1 is only the first readout. Retatrutide's registrational program is unusually broad — it studies obesity alongside several linked conditions, which is why the compound is watched so closely in metabolic research:
| Trial | Research focus |
|---|---|
| TRIUMPH-1 | Pivotal Phase 3 efficacy readout |
| TRIUMPH-2 — reported Jul 2026 | Type 2 diabetes with obesity/overweight (80-week readout) |
| TRIUMPH-3 — reported Jul 2026 | Severe obesity with established cardiovascular disease (80-week readout; neutral MACE result) |
| TRIUMPH-4 | Obesity with knee osteoarthritis (completed 2025) |
| TRIUMPH-Outcomes | Obesity with cardiovascular disease or chronic kidney disease (~10,000 participants) |
In other words, the program is testing retatrutide not just for weight but across obstructive sleep apnea, knee osteoarthritis, and cardiovascular/kidney outcomes, with further trials reporting through 2026. The rationale and design of these registrational trials are published in the peer-reviewed literature (see references). ↑ Back to top
Safety & Adverse Events in Trials
As with other incretin agonists, the adverse events reported in the retatrutide trials were predominantly gastrointestinal and concentration-dependent. In the TRIUMPH-1 Phase 3 topline results, the most common adverse events in the highest arm were:
| Adverse event (TRIUMPH-1, highest arm) | Reported rate |
|---|---|
| Nausea | ~42% |
| Diarrhea | ~32% |
| Constipation | ~26% |
| Vomiting | ~25% |
| Treatment discontinuation | 11.3% (vs 4.9% placebo) |
For a fuller treatment of the reported tolerability profile, consult the primary trial publications. All figures describe outcomes in the supervised clinical trial population and are reported here for scientific reference only. ↑ Back to top
The July 2026 readouts showed a broadly consistent tolerability profile. In TRIUMPH-2 the most common adverse events were diarrhea (27.4–33.6%), nausea (13.7–28.0%) and constipation (14.0–16.8%), with treatment discontinuation of 3.8–11.6% versus 4.9% for placebo. In the higher-risk TRIUMPH-3 population, diarrhea (24.4–30.1%), nausea (21.7–22.4%) and constipation (15.7–18.0%) were most common, with discontinuation of 9.8–13.5% versus 4.8% for placebo. As in TRIUMPH-1, the events were predominantly gastrointestinal and concentration-dependent.
Retatrutide vs Tirzepatide vs Semaglutide
The three compounds represent successive generations of incretin-based research. The table lists receptor targets and development status for each compound.
| Compound | Receptor targets | Developer | Status |
|---|---|---|---|
| Retatrutide | GIP / GLP-1 / glucagon (triple) | Eli Lilly | Phase 3 (investigational) |
| Tirzepatide | GIP / GLP-1 (dual) | Eli Lilly | Approved (other markets) |
| Semaglutide | GLP-1 (single) | Novo Nordisk | Approved (other markets) |
The progression from single to dual to triple receptor engagement is examined in full in our Semaglutide vs Tirzepatide vs Retatrutide comparison. ↑ Back to top
Research Applications
In a laboratory setting retatrutide is used as a reference compound for investigating triple-receptor incretin pharmacology: comparative agonist potency across GIP, GLP-1, and glucagon receptors; receptor-signaling and downstream metabolic-pathway studies; and structure–activity work on lipidated long-acting peptides. Its position as the first triple agonist in Phase 3 makes it a frequent comparator in metabolic and energy-expenditure research alongside tirzepatide and semaglutide. These are research contexts only and do not describe any use in humans or animals. ↑ Back to top
Purity, COA & Third-Party Testing
For research integrity, compound purity is critical: impurities can confound assay results, introduce off-target activity, and undermine reproducibility. All three vial formats have a published, batch-specific certificate.
| Format | Lot | Purity | Net content | Testing laboratory |
|---|---|---|---|---|
| 10 mg | RETA-0626-01 | 99.68% | 11.88 mg | Testides, Toronto — HPLC-UV 214 nm |
| 20 mg | CS-re20-0710 | 99.643% | 24.51 mg | Janoshik Analytical — blind test |
| 30 mg | CS-re30-0718 | 99.751% | 34.20 mg | Janoshik Analytical — blind test |
What a blind test is, and why it is the stronger result
Both larger lots were submitted to Janoshik as a common GLP-1 peptide blind test: the laboratory was given three candidate compounds — semaglutide, tirzepatide and retatrutide — and was not told which of the three the sample was. In both cases it identified the material as retatrutide from its own analysis.
An ordinary assay starts from the label. The lab is told the vial is supposed to contain retatrutide and reports whether it found retatrutide, so the result can never establish much more than agreement with the paperwork it began with. A blind test cannot confirm a label it was never shown, which closes the gap between what the vial claims and what the report establishes. It costs no more to publish than a standard assay.
The certificates behind these lots
The 20 mg and 30 mg certificates were issued by Janoshik Analytical and are published under Janoshik ref #207689 for lot CS-re20-0710 and Janoshik ref #210575 for lot CS-re30-0718. The 10 mg lot is verified by Testides in Toronto, and our Testides confirmation on the two larger lots is pending.
Net content on all three lots assayed above label weight: 11.88 mg, 24.51 mg and 34.20 mg against 10 mg, 20 mg and 30 mg labels respectively. Net content is the assayed mass of peptide in the vial as reported by the laboratory.
All three certificates are published on the lab results page. If you want to validate a lot yourself, our guide on where to get research peptides tested in Canada walks through independent verification, and our supplier evaluation guide covers how to score a batch-specific certificate. ↑ Back to top
Handling (Research Context)
Retatrutide is supplied as a lyophilized powder. Handling, solvent selection, and preparation of working solutions are determined by each laboratory’s own validated protocols and the documentation supplied with the material. This page does not provide preparation, solution, or administration instructions. Identity and purity should be confirmed against the Certificate of Analysis before a lot enters any protocol. ↑ Back to top
Storage & Stability
Lyophilized retatrutide is the most stable form: kept sealed, cool, and away from light, freeze-dried peptide powder is stable long-term, and many labs store powder frozen. Store the sealed vial refrigerated at 2–8 °C and protected from light for long-term stability, and avoid repeated warming or freeze-thaw cycling. Inspect for cloudiness or particulates before use in any assay. ↑ Back to top
Is Retatrutide Available or Approved in Canada?
No — retatrutide is not approved by Health Canada or the U.S. FDA as of 2026. It remains an investigational compound in Eli Lilly's Phase 3 program, so there is no prescription or therapeutic version available in Canada, and it cannot be lawfully sold or used for human consumption.
What is available in Canada is retatrutide as a research chemical for laboratory use only — a lyophilized reference material supplied to researchers and clearly labelled research-use-only. That is the only lawful route of access, and it carries the responsibilities that apply to any research compound. For the regulatory picture across the whole category, see our guide on whether research peptides are legal in Canada.
Sourcing it as a research material domestically, rather than from overseas, avoids customs seizures and long transit — the practical reasons Canadian researchers buy in-country, covered next. ↑ Back to top
Why Canadian Researchers Source Domestically
- No customs seizures — domestic shipments avoid border inspection delays and the confiscation risk that affects international peptide orders.
- Faster shipping — in-country logistics mean material arrives in days, not weeks, protecting cold-chain integrity and research timelines. Orders are dispatched within 48 hours from British Columbia and typically arrive in 2–8 business days, free and tracked, with no minimum order.
- CAD pricing — transparent Canadian-dollar pricing with no surprise currency conversion, duties, or brokerage fees.
For the full picture, see our guide to buying research peptides in Canada. ↑ Back to top
Retatrutide Price in Canada (2026)
Retatrutide 10 mg is $90.00 CAD — $9.00 per mg. Two larger research formats are now in stock: 20 mg at $140.00 CAD ($7.00/mg) and 30 mg at $180.00 CAD ($6.00/mg), which is the lowest per-mg price in the range. All three carry a published, batch-specific certificate. All prices are in Canadian dollars and include free, tracked Canada-wide shipping with no minimum order.
| Format | Price (CAD) | Per mg | Availability | Lot and verified purity |
|---|---|---|---|---|
| Retatrutide 10 mg | $90.00 | $9.00/mg | In stock | RETA-0626-01 — 99.68% (Testides) |
| Retatrutide 20 mg | $140.00 | $7.00/mg | In stock | CS-re20-0710 — 99.643% (Janoshik, blind test) |
| Retatrutide 30 mg | $180.00 | $6.00/mg | In stock — best per-mg price | CS-re30-0718 — 99.751% (Janoshik, blind test) |
Per-mg cost is the fairest way to compare vial sizes: the 30 mg format works out about 33% cheaper per milligram than the 10 mg vial, and the 20 mg about 22% cheaper, which matters for laboratories running longer characterisation work from a single lot. Buying several small vials no longer narrows that gap. Three 10 mg vials come to $270.00, and even with the automatic 10% discount that applies at three or more units that is $243.00, against $180.00 for a single 30 mg vial — the larger format is $63.00 cheaper for the same 30 mg. Two 10 mg vials come to $180.00, with no quantity discount at two units, against $140.00 for the 20 mg vial, a $40.00 difference. Each format is released with its own batch-specific Certificate of Analysis; the purity section above sets out which laboratory issued each one. ↑ Back to top
Shop Retatrutide 10mg — $90.00 CAD →
Frequently Asked Questions
How much does retatrutide cost in Canada?
At ThePeptide, retatrutide 10 mg is $90.00 CAD ($9.00 per mg). Two larger formats are also in stock: 20 mg at $140.00 CAD ($7.00 per mg) and 30 mg at $180.00 CAD ($6.00 per mg), the best per-mg price in the range. Every order ships free and tracked across Canada with no minimum order.
Who tested the retatrutide 20 mg and 30 mg lots?
Janoshik Analytical did. Both were run as a common GLP-1 peptide blind test: the laboratory was given semaglutide, tirzepatide and retatrutide as candidates, was not told which the sample was, and identified retatrutide from its own analysis. Lot CS-re20-0710 returned 99.643% purity and 24.51 mg of net content against a 20 mg label; lot CS-re30-0718 returned 99.751% and 34.20 mg against a 30 mg label. The two certificates are published under Janoshik ref #207689 and #210575. Our Testides confirmation on both lots is pending.
Is retatrutide legal in Canada for research use?
Retatrutide is sold in Canada strictly for laboratory and research use only. It is not approved by Health Canada as a therapeutic product and is not intended for human or animal consumption. Researchers are responsible for handling it in compliance with applicable laws and institutional guidelines governing research chemicals.
Is retatrutide available or approved in Canada?
No. Retatrutide is investigational and is not approved by Health Canada or the FDA as of 2026, so there is no prescription or therapeutic version in Canada. It is available only as a research-use-only laboratory compound. See our guide on whether research peptides are legal in Canada.
What is retatrutide's half-life?
Retatrutide has an elimination half-life of approximately six days (about 144 hours), driven by fatty-acid lipidation and reversible albumin binding. That long half-life underlies an extended duration of action, with steady state reached over roughly four to five weeks in pharmacokinetic studies.
What is the difference between retatrutide and tirzepatide?
Retatrutide is a triple agonist activating GIP, GLP-1, and glucagon receptors; tirzepatide is a dual agonist acting on only GIP and GLP-1. The added glucagon arm is associated with increased energy expenditure and is the main structural distinction. See the full tirzepatide guide.
What is retatrutide's CAS number and molecular class?
Retatrutide (development code LY-3437943) has CAS number 2381089-83-2 and is a 34-amino-acid lipidated peptide classed as a triple GLP-1 / GIP / glucagon receptor agonist, developed by Eli Lilly.
What purity is this retatrutide?
The 10 mg lot is independently verified at 99.68% purity by HPLC-UV at 214 nm, lot RETA-0626-01, tested by the third-party laboratory Testides. The 20 mg lot CS-re20-0710 returned 99.643% and the 30 mg lot CS-re30-0718 returned 99.751%, both on a Janoshik Analytical blind test, with our Testides confirmation on those two pending. All three are published on the lab results page.
What did TRIUMPH-2 and TRIUMPH-3 show?
In topline results reported July 23, 2026, TRIUMPH-2 (adults with type 2 diabetes) and TRIUMPH-3 (adults with severe obesity and established cardiovascular disease) reported their 80-week endpoints; see the primary releases. Both describe outcomes for a research compound, not dosing guidance.
Does retatrutide reduce cardiovascular events?
Not demonstrated yet. In TRIUMPH-3 the pre-specified MACE-5 hazard ratio was 0.82 (95% CI 0.55–1.22) — a neutral, non-significant result, because cardiovascular events occurred less often than expected in both arms. Changes in cardiovascular risk factors such as triglycerides, non-HDL cholesterol and hs-CRP were also reported. Whether that translates into fewer events is the question of the larger TRIUMPH-Outcomes trial.
What were the main side effects reported in retatrutide trials?
The most common adverse events in TRIUMPH-1 were gastrointestinal: nausea (~42%), diarrhea (~32%), constipation (~26%), and vomiting (~25%), with treatment discontinuation of 11.3% versus 4.9% for placebo. More detail is in the primary trial publications.
What is the TRIUMPH trial?
TRIUMPH is Eli Lilly's Phase 3 clinical program for retatrutide. TRIUMPH-1 (announced May 2026) reported its 104-week weight-loss endpoint in 2,339 participants; TRIUMPH-2 and TRIUMPH-3 (reported July 2026) added data in type 2 diabetes and in participants with established cardiovascular disease. Further trials, including TRIUMPH-Outcomes, are ongoing.
How is retatrutide stored?
Store the sealed lyophilized vial cool, dark and refrigerated for long-term. Protect from light and avoid freeze-thaw cycling. Always follow your laboratory's storage protocols.
Who developed retatrutide?
Retatrutide was developed by Eli Lilly and Company under the code LY-3437943. It is investigational and has not received marketing approval from Health Canada, the FDA, or other regulators as of 2026.
Why does purity matter for research peptides?
High, independently verified purity reduces the risk that impurities confound results, introduce off-target activity, or compromise reproducibility. A third-party HPLC figure and COA give confidence in each lot's identity and consistency before work begins.
How does retatrutide compare to semaglutide and tirzepatide overall?
By receptor target: semaglutide (GLP-1, single), tirzepatide (GIP/GLP-1, dual), retatrutide (triple). Our comparison guide covers the full analysis.
Related Research Resources
- Retatrutide 10mg (product page & COA)
- Retatrutide 20mg — $140 ($7.00/mg) · Retatrutide 30mg — $180 ($6.00/mg)
- Published lot certificates for all three formats
- Semaglutide vs Tirzepatide vs Retatrutide comparison
- Tirzepatide Canada research guide · Semaglutide Canada research guide
- Where to get research peptides tested in Canada
- How to buy research peptides in Canada
References
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. DOI: 10.1056/NEJMoa2301972. Read the paper.
- Eli Lilly and Company. "TRIUMPH-1 Phase 3 topline results." May 2026. investor.lilly.com.
- Eli Lilly and Company. "Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C" (TRIUMPH-2 and TRIUMPH-3 topline results). July 23, 2026. investor.lilly.com.
- HCPLive. "Retatrutide Meets Phase 3 Weight-Loss Endpoints in 2 Obesity Trials." July 2026. hcplive.com.
- Pharmaceutical Executive. "Retatrutide Delivers Up to 22.6% Weight Loss in Two New Phase III Trials." July 2026. pharmexec.com.
- Fierce Biotech. "Lilly's triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clear" (TRIUMPH-3 MACE analysis). July 2026. fiercebiotech.com.
- The American Journal of Managed Care (AJMC). "Retatrutide Achieves Up to 30.3% Average Weight Loss in Phase 3 TRIUMPH-1 Trial." ajmc.com.
- Retatrutide (LY-3437943), CAS 2381089-83-2 — compound record. Reference entry.
- ClinicalTrials.gov. TRIUMPH program listings, including NCT05931367 (retatrutide once weekly). clinicaltrials.gov.
- Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: rationale and design of the TRIUMPH registrational clinical trials. PubMed. PMID: 41090431.
- Eli Lilly and Company. "Retatrutide delivered weight loss and osteoarthritis pain relief in first successful Phase 3 trial" (TRIUMPH-4). 2026. investor.lilly.com.